{"url_path":"/sec/inti/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1042418/0001493152-26-023622-index.html","accession_number":"0001493152-26-023622","cik":"0001042418","ticker":"INTI","issuer_name":"Inhibitor Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1042418/0001493152-26-023622-index.html","primary_entity_key":"0001042418","primary_entity_name":"Inhibitor Therapeutics, Inc."},"word_count":55,"has_tables":true,"body_markdown":"**Item\n5. Other Information.**\n\n \n\nDuring\nthe quarter ended March 31, 2026, no directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) of the\nCompany adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,”\nas each term is defined in Item 408(a) of Regulation S-K.\n\n \n\n13"}